Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ArQule

- PMLiVE

NICE finally set to back wider use of Ferring’s Firmagon

And acknowledges drug's benefits for prostate cancer that spreads to the spine

Bristol-Myers Squibb (BMS) building

BMS to explore new options for its immuno-oncology drug Opdivo

Partners with PsiOxis to research its use with enadenotucirev

- PMLiVE

Merck & Co signs cancer vaccines research deal for Keytruda

Will work on range of personalised vaccines to complement its blockbuster

Celgene building

Celgene takes aim at cancer innovation with new US research consortium

Academic tie-up aims to develop new therapeutics and diagnostics

- PMLiVE

Merck starts pivotal trials of new antibiotic combination

Continues testing after positive phase II results for relebactam addition 

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

- PMLiVE

Ariad files early marketing application for brigatinib

Second-line lung cancer therapy could be on the market by early 2017

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

Sanofi reception

Sanofi moves to replace Medivation board

Ramps up efforts to seize control of its US biopharma takeover target

- PMLiVE

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications

Roche Basel Switzerland

Roche gets EU okay for Avastin/Tarceva combination

Lung cancer therapy ‘significantly’ extends progression-free survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links